Standard BioTools Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
539
- Stock Symbol
-
LAB
- Investments
-
4
- Share Price
-
$2.00
- (As of Tuesday Closing)
Standard BioTools General Information
Description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact Information
Website
www.standardbio.comCorporate Office
- 2 Tower Place
- Suite 2000
- San Francisco, CA 94080
- United States
Corporate Office
- 2 Tower Place
- Suite 2000
- San Francisco, CA 94080
- United States
Standard BioTools Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.00 | $1.99 | $1.21 - $3.05 | $742M | 371M | 3.34M | -$0.89 |
Standard BioTools Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 285,261 | 450,830 | 321,964 | 375,602 |
| Revenue | 136,300 | 106,340 | 97,948 | 130,581 |
| EBITDA | (108,932) | (54,457) | (173,570) | (44,266) |
| Net Income | (118,648) | (74,656) | (190,098) | (59,237) |
| Total Assets | 708,732 | 323,067 | 390,310 | 275,214 |
| Total Debt | 90,550 | 98,210 | 102,655 | 111,648 |
Standard BioTools Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Standard BioTools Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Standard BioTools Comparisons
Industry
Financing
Details
000 00
000000
Standard BioTools Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 10x Genomics | Private Equity-Backed | Pleasanton, CA | 0000 | 00.000 | 000000000 | |
| Illumina | Formerly VC-backed | San Diego, CA | 0000 | 00.000 | 000000000 00 | 00.000 |
| Sphere Fluidics | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
| HTG Molecular Diagnostics | Formerly VC-backed | Tucson, AZ | 00 | 00000 | 0000000000. | |
| Luminex | Corporate Backed or Acquired | Austin, TX | 0000 | 000.00 | 000000&0 | 000.00 |
Standard BioTools Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Standard BioTools Patents
Standard BioTools Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-D1038429-S1 | Scientific instrument | Active | 15-Oct-2021 | 00 | |
| CA-3224439-A1 | An angled illumination system for microfluidic devices | Pending | 02-Jul-2021 | 000000000 | |
| EP-4363917-A1 | An angled illumination system for microfluidic devices | Pending | 02-Jul-2021 | 000000000 | |
| US-20220017953-A1 | Parallelized sample processing and library prep | Pending | 20-Feb-2020 | 0000000000 | 0 |
| CA-3168563-A1 | Parallelized sample processing and library prep | Pending | 20-Feb-2020 | B01L7/52 |
Standard BioTools Executive Team (23)
| Name | Title | Board Seat |
|---|---|---|
| Michael Egholm Ph.D | Chief Executive Officer, President & Board Member | |
| Hanjoon Alex Kim | Chief Financial Officer, Finance & Founder | |
| Shane Bowen Ph.D | Chief Technology Officer | |
| Jeremy Davis | Chief Commercial Officer | |
| Chris Leidel | Vice President, Business Development |
Standard BioTools Board Members (21)
| Name | Representing | Role | Since |
|---|---|---|---|
| Eli Casdin | Casdin Capital | Board Member | 000 0000 |
| Fenel Eloi | Self | Board Member | 000 0000 |
| Frank Witney Ph.D | Self | Board Member | 000 0000 |
| Kathy Hibbs JD | Self | Board Member | 000 0000 |
| Michael Egholm Ph.D | Standard BioTools | Chief Executive Officer, President & Board Member | 000 0000 |
Standard BioTools Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Standard BioTools Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Standard BioTools Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SomaLogic | 05-Jan-2024 | 0000000000 | 00000 | Biotechnology | 0000000 0 |
| InstruNor | 17-Jan-2020 | 0000000000 | 00.00 | Diagnostic Equipment | |
| DVS Sciences | 13-Feb-2014 | 0000000000 | 00000 | Discovery Tools (Healthcare) | 00000 000 |
| Helicos Biosciences (Patent portfolio) | 28-Jun-2013 | Corporate Asset Purchase | 00.00 | Buildings and Property |
Standard BioTools Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| SomaLogic | Biotechnology | Boulder, CO | 0000 |
Standard BioTools ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
25.27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
Percentile
Laboratory Equipment and Services
Subindustry
00 of 67
Rank
Percentile
Standard BioTools FAQs
-
When was Standard BioTools founded?
Standard BioTools was founded in 1999.
-
Who is the founder of Standard BioTools?
Hanjoon Alex Kim, Gajus Worthington, and Stephen Quake Ph.D are the founders of Standard BioTools.
-
Who is the CEO of Standard BioTools?
Michael Egholm Ph.D is the CEO of Standard BioTools.
-
Where is Standard BioTools headquartered?
Standard BioTools is headquartered in San Francisco, CA.
-
What is the size of Standard BioTools?
Standard BioTools has 539 total employees.
-
What industry is Standard BioTools in?
Standard BioTools’s primary industry is Discovery Tools (Healthcare).
-
Is Standard BioTools a private or public company?
Standard BioTools is a Public company.
-
What is Standard BioTools’s stock symbol?
The ticker symbol for Standard BioTools is LAB.
-
What is the current stock price of Standard BioTools?
As of 10-Sep-2024 the stock price of Standard BioTools is $2.00.
-
What is the current market cap of Standard BioTools?
The current market capitalization of Standard BioTools is $742M.
-
What is Standard BioTools’s current revenue?
The trailing twelve month revenue for Standard BioTools is $136M.
-
Who are Standard BioTools’s competitors?
10x Genomics, Illumina, Sphere Fluidics, HTG Molecular Diagnostics, and Luminex are some of the 22 competitors of Standard BioTools.
-
What is Standard BioTools’s annual earnings per share (EPS)?
Standard BioTools’s EPS for 12 months was -$0.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
